Crinetics Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $17.7200
- Today's High:
- $18.8800
- Open Price:
- $18.4000
- 52W Low:
- $15.91
- 52W High:
- $28.95
- Prev. Close:
- $18.5000
- Volume:
- 239613
Company Statistics
- Market Cap.:
- $0.968 billion
- Book Value:
- 7.19
- Revenue TTM:
- $0.005 billion
- Operating Margin TTM:
- -2917%
- Gross Profit TTM:
- $-0.083 billion
- Gross Profit TTM:
- $-0.083 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.5%
- Return on Equity TTM:
- -46.2%
Company Profile
Crinetics Pharmaceuticals Inc had its IPO on 2018-07-18 under the ticker symbol CRNX.
The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Crinetics Pharmaceuticals Inc has a staff strength of 0 employees.
Stock update
Shares of Crinetics Pharmaceuticals Inc opened at $18.4 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $17.72 - $18.88, and closed at $18.01.
This is a -2.65% slip from the previous day's closing price.
A total volume of 239,613 shares were traded at the close of the day’s session.
In the last one week, shares of Crinetics Pharmaceuticals Inc have increased by +0.06%.
Crinetics Pharmaceuticals Inc's Key Ratios
Crinetics Pharmaceuticals Inc has a market cap of $0.968 billion, indicating a price to book ratio of 2.61 and a price to sales ratio of 208.28.
In the last 12-months Crinetics Pharmaceuticals Inc’s revenue was $0.005 billion with a gross profit of $-0.083 billion and an EBITDA of $-0.135 billion. The EBITDA ratio measures Crinetics Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Crinetics Pharmaceuticals Inc’s operating margin was -2917% while its return on assets stood at -26.5% with a return of equity of -46.2%.
In Q2, Crinetics Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Crinetics Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- None
Its diluted EPS in the last 12-months stands at $-2.835 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Crinetics Pharmaceuticals Inc’s profitability.
Crinetics Pharmaceuticals Inc stock is trading at a EV to sales ratio of 129.5 and a EV to EBITDA ratio of -4.471. Its price to sales ratio in the trailing 12-months stood at 208.28.
Crinetics Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Crinetics Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Crinetics Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Crinetics Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Crinetics Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Crinetics Pharmaceuticals Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $18.01
- 52-Week High
- $28.95
- 52-Week Low
- $15.91
- Analyst Target Price
- $43
Crinetics Pharmaceuticals Inc stock is currently trading at $18.01 per share. It touched a 52-week high of $28.95 and a 52-week low of $28.95. Analysts tracking the stock have a 12-month average target price of $43.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Crinetics Pharmaceuticals Inc
Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)
Most Active
Top Gainers
Top Losers
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.